Allergen-specific immunotherapy (AIT) is currently the only treatment for IgE-mediated allergic diseases that modifies the cellular and humoral responses of allergic patients and leads to a long-term amelioration of allergic symptoms. Conventional AIT is based on a high number of regular subcutaneous injections of allergen extracts for up to 3 years. The time-consuming and longlasting treatment schedule impairs patient compliance. 1 Using Toll-like receptor (TLR) ligands as adjuvants in AIT vaccines might dramatically reduce the number of injections by means of activation of the innate immune system and subsequent stronger counterregulation of the disease-eliciting T H 2 response. [2] [3] [4] For example, supplementation of allergen vaccines with the TLR4 ligand monophosphoryl lipid A strongly promoted T H 1-like responses 5 and achieved clinical improvement in patients after only 4 preseasonal injections. [6] [7] [8] [9] Direct conjugation of TLR ligands to allergens has been shown to amplify their immunomodulatory capacity. [10] [11] [12] The TLR5 ligand flagellin, the main component of bacterial flagella, is used as an adjuvant in various vaccines. As a protein, flagellin can be genetically fused to antigens, and such hybrid proteins have been demonstrated to induce strong innate and adaptive immune responses. [12] [13] [14] Although TLR5 activation does not enhance antigen uptake, 4 a flagellin fusion protein with green fluorescent protein has been shown to be efficiently taken up, processed, and presented by dendritic cells inducing specific immune responses against the per se nonimmunogenic green fluorescent protein. 15 This enhanced immunogenicity has been believed to be caused by the TLR5-upregulated expression of MHC and costimulatory molecules on the surfaces of antigen-presenting cells that take up and present the antigen. Flagellin fusion proteins with allergens might represent immunogenic vaccines for AIT. 16, 17 Indeed, it has been demonstrated that the fusion protein of flagellin from Listeria monocytogenes and ovalbumin but not the mixture of both components suppresses the allergic T H 2 response and allergy-related symptoms in a mouse model of intestinal allergy. AIT with rBet v 1.0101 (Bet v 1) has achieved a similar clinical improvement of birch pollen allergy as AIT with birch pollen extract in a multicenter, randomized, double-blind, placebocontrolled trial. 21 Thus Bet v 1 substituted for natural birch pollen extract but per se did not exhibit a superior effectivity. To enhance its immunogenicity, we fused Bet v 1 to flagellin from Salmonella typhimurium (fliC) because the immunostimulatory capacity of this flagellin has been proved in various studies. 22 We substituted its hypervariable region, which is thought to promote production of neutralizing antibodies 23 that downregulate TLR5 signaling, with a short-turn motif to reduce its size and to keep the close proximity of the N-and C-termini necessary for TLR5 binding. Deletion of the hypervariable region did not abrogate the adjuvant effect because the resulting truncated flagellin, NtCFlg, still activated TLR5 and was fused to either the N-or C-terminus of Bet v 1, which was termed NtCFlg-Bet v 1 and Bet v 1-NtCFlg, respectively, to assess possible position effects. Both fusion proteins were characterized and compared with regard to their ability (1) to target TLR5, (2) to activate human monocyte-derived dendritic cells (mdDCs), (3) to bind Bet v 1-specific IgE antibodies and induce IgE-mediated effector cell activation, and (4) to activate Bet v 1-specific T cells. In addition, we immunized mice with the fusion proteins in the absence or presence of aluminum hydroxide (alum) to investigate their intrinsic adjuvanticity and analyzed whether murine antibodies were able to inhibit the binding of patient-derived IgE to Bet v 1.
METHODS
The cloning of constructs is described in the Methods section and Table E1 in this article's Online Repository at www.jacionline.org.
TLR activation assays
HEK293 cell lines stably transfected with human TLR5 (HEK-hTLR5 cells) or TLR4, MD2, and CD14 (HEK-hTLR4/MD2-CD14 cells; both from InvivoGen, San Diego, Calif) were cultured in Dulbecco modified Eagle medium High Glucose supplemented with 10% FCS (both from PAA Laboratories, Pasching, Austria) and selective antibiotics, as described in the manufacturer's instructions (all InvivoGen). Cells (4 3 10 4 /96-well plate; Corning, New York, NY) were stimulated with titrated amounts of Bet v 1 (Biomay, Vienna, Austria), recombinant fliC (InvivoGen), NtCFlg, Bet v 1-NtCFlg, or NtCFlg-Bet v 1 for 20 hours in triplicate. Secreted IL-8 was quantified by means of ELISA. For this, 96-well plates (NUNC Maxisorp; Thermo Fisher Scientific, Waltham, Mass) were coated with the anti-human IL-8 antibody M801 (Thermo Fisher Scientific) overnight and blocked for 1 hour at room temperature in 4% BSA in PBS-Tween 0.05%. Samples and standards (Thermo Fisher Scientific) were added in blocking buffer for 1 hour at room temperature. Bound IL-8 was detected with biotinylated IL-8 antibody (Thermo Fisher Scientific), poly-horseradish peroxidase streptavidin (Thermo Fisher Scientific), and TMB solution (Millipore, Billerica, Mass).
Patients
To be included, patients had to have a doctor's diagnosis of birch pollen allergy based on rhinoconjunctivitis in the spring, positive skin prick test responses to birch pollen extract (ALK-Abell o, Hørsholm, Denmark), and Bet v 1-specific IgE levels of greater than 5 kU A /L (ImmunoCAP, Thermo Fisher Scientific; see Table E2 in this article's Online Repository at www.jacionline. org). The study was approved by the local ethics committee. Blood donors provided written informed consent. mdDCs mdDCs were generated, as described previously. 24 In preliminary experiments immature mdDCs from 5 subjects were treated with titrated concentrations of Bet v 1-NtCFlg, NtCFlg-Bet v 1, and NtCFlg (100 nmol/L to 0.01 nmol/L) for 48 hours and analyzed for upregulation of CD83, CD80, CD86, and CD40 by using flow cytometry. The highest values of upregulation were found with 0.01 nmol/L NtCFlg, 0.1 nmol/L Bet v 1-NtCFlg, and 1 nmol/L NtCFlg-Bet v 1, respectively (data not shown). These concentrations were then used to stimulate mdDCs from 14 patients with birch pollen allergy. Bet v 1 (100 nmol/L) and fliC (3 nmol/L) served as controls.
T-cell stimulation
Bet v 1-specific T-cell lines (TCLs) were generated from PBMCs (1.5 3 10 6 /well) with 10 mg/mL of Bet v 1, as previously described. 25 Cryopreserved Bet v 1-specific T-cell clones (TCCs) with determined epitope specificity (Table I) 1 T cells were purified from PBMCs by using the Na€ ıve CD4
1
T cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany), resulting in greater than 90% CD4 1 CD45RA 1 cells. These cells were cocultured for 6 days with irradiated autologous mdDCs that had been stimulated with Bet v 1 (100 nmol/L) or Bet v 1-NtCFlg (0.1 nmol/L) for 24 hours. 4 Cytokine levels in supernatants were analyzed by using the Luminex System 100 (Luminex, Austin, Tex).
Inhibition ELISA
Sera were preincubated with equimolar concentrations of Bet v 1, NtCFlg, Bet v 1-NtCFlg, or NtCFlg-Bet v 1 (300 nmol/L to 480 pmol/L) for 4 hours at room temperature and added to ELISA plates coated with Bet v 1 (1 mg/mL) overnight and saturated with 1% human serum albumin for 6 hours. Bound IgE was detected with alkaline phosphatase-conjugated anti-human IgE (BD Biosciences, Heidelberg, Germany) and PNPP (Sigma-Aldrich, St Louis, Mo). Percentage of inhibition was calculated as follows:
% Inhibition 5 1002ðOD½Serum with inhibitor= OD½Serum without inhibitorÞ3100:
Basophil activation test
Heparinized blood of 7 donors with birch pollen allergy was incubated with titrated amounts of Bet v 1, NtCFlg, Bet v 1-NtCFlg, or NtCFlg-Bet v 1 (600 nmol/L to 6 pmol/L) in HEPES Calcium Buffer (pH 7.4) containing 2 ng/ mL IL-3 for 15 minutes at 378C. For inhibition experiments, Bet v 1 (1.2 and 0.12 ng in 2 mL of buffer) was incubated with pooled mouse sera (5 mL) for 1 hour at 378C. The reaction was stopped with HEPES/EDTA (20 mmol/L) buffer, and cells were stained with CD123-fluorescein isothiocyanate, CCR3-allophycocyanin, and CD63-phycoerythrin (all from BioLegend, San Diego, Calif), followed by erythrocyte lysis. Basophils were defined as CD123
1 CCR3 1 cells. Basophil activation was expressed as a percentage of 
Immunization of mice

Murine immune responses
ELISA plates were coated with Bet v 1 (1 mg/mL) in carbonate buffer (pH 9.6). Sera were diluted 1:1000 for detection of IgG 1 and IgG 2a and 1:20 for detection of IgE antibodies. Rat anti-mouse IgE, IgG 1 , IgG 2a (all from BD PharMingen, San Jose, Calif), horseradish peroxidase-conjugated goat antirat IgG (GE Healthcare, Vienna, Austria), and ABTS (Sigma-Aldrich) were used for detection. Absorbance was measured at 405 nm. Single-cell suspensions from spleens (1 3 10 6 /mL) were stimulated in triplicate with Bet v 1 (10 mg/mL), and proliferation was assessed by means of incorporation of tritiated thymidine after 72 hours. Moreover, splenocytes (8 3 10 6 /mL) were stimulated with Bet v 1 (10 mg/mL). Supernatants were collected after 48 hours, and IL-4 and IFN-g levels were measured with the Luminex system 100.
Statistics
Data were analyzed with IBM SPSS 20.0 software (SPSS, Chicago, Ill). Statistical differences were determined by using the Wilcoxon signed-rank test or paired-sample t test and considered statistically significant at a P value of less than .05. Data from duplicate and triplicate experiments are shown as means with SDs. (Fig 1, A) . NtCFlg was fused to either the N-or C-terminus of Bet v 1, which was termed NtCFlg-Bet v 1 or Bet v 1-NtCFlg, respectively. Both 48-kDa proteins induced IL-8 secretion in HEK-hTLR5 cells, with slightly stronger responses to Bet v 1-NtCFlg (Fig 1, A) . None of the proteins induced IL-8 secretion in HEK-hTLR4/MD2-CD14 cells, demonstrating that the recombinant proteins were endotoxin free (data not shown).
Next, immature mdDCs were stimulated with optimal concentrations of each protein, as indicated in the Methods section. Bet v 1 did not induce maturation of mdDCs, whereas Bet v 1-NtCFlg, NtCFlg-Bet v 1, NtCFlg, and fliC significantly enhanced expression of CD83, CD80, CD86, and CD40 (P < .001; Fig 1, B) . Notably, 10-fold less Bet v 1-NtCFlg than NtCFlg-Bet v 1 was sufficient to achieve the same expression levels of surface markers on mdDCs.
Bet v 1-NtCFlg and NtCFlg-Bet v 1 show T cellactivating capacity
Bet v 1-specific TCLs from 6 patients with birch pollen allergy were stimulated with equimolar amounts of Bet v 1, Bet v 1- (Table II) .
To assess whether antigen processing of Bet v 1-NtCFlg produced the most relevant T cell-activating regions, 27 we used 11 Bet v 1-specific TCCs from 5 different donors with birch pollen allergy specific for epitopes distributed over the entire sequence of Bet v 1 (Table I ). All TCCs, except TCC9, responded with a significantly higher proliferation to Bet v 1-NtCFlg than to Bet v 1 (P < .005). As expected, NtCFlg did not induce proliferative responses in Bet v 1-specific T-cell cultures. We also analyzed the levels of IL-4, IL-10, and IFN-g in Bet v 1-specific TCCs. However, none of these presumably end-differentiated clones changed their cytokine profile in response to a 1-time stimulation with Bet v 1-NtCFlg (data not shown).
Next, we cocultured naive T cells from 3 patients with birch pollen allergy with autologous mdDCs stimulated with Bet v 1 and Bet v 1-NtCFlg, respectively, and assessed their production of IL-4, IL-5, IL-10, IL-13, and IFN-g. However, IL-4 and IL-10 were not detected in any of the cultures. Levels of IL-5, IL-13 and IFN-g are summarized in Table III , and these results revealed that mdDCs stimulated with the fusion protein displayed a more pronounced polarizing capacity than Bet v 1-stimulated mdDCs. Furthermore, mdDCs stimulated with Bet v 1-NtCFlg promoted IFN-g production by T cells, which was marginal in cultures polarized with Bet v 1-stimulated mdDCs.
Bet v 1-NtCFlg and NtCFlg-Bet v 1 are hypoallergenic
Sera from 11 patients with birch pollen allergy were preincubated with the fusion proteins or Bet v 1 to assess inhibition of IgE binding to plate-bound Bet v 1 (Fig 2, A) . The fusion proteins displayed a significantly lower inhibitory capacity than Bet v 1. Bet v 1-NtCFlg bound significantly less IgE than NtCFlg-Bet v 1 at low concentrations.
The efficacy to induce IgE-mediated effector cell activation was tested in basophil activation tests of 7 donors with birch pollen allergy (Fig 2, B) . Bet v 1-NtCFlg and NtCFlg-Bet v 1 induced significantly less basophil activation than Bet v 1 at 6, 60, and 600 pmol/L (P < .05). No significant difference between the fusion proteins was observed.
Bet v 1-NtCFlg and NtCFlg-Bet v 1 show intrinsic adjuvanticity
BALB/c mice were immunized 5 times intraperitoneally with equimolar doses of Bet v 1, Bet v 1-NtCFlg, NtCFlg-Bet v 1, or the mixture of Bet v 1 and NtCFlg either without or adsorbed to alum. Sera were regularly taken and assessed for Bet v 1-specific IgG 1 , IgG 2a , and IgE levels. After 2 to 3 immunizations with alum, all 3 Bet v 1-specific antibody subclasses were detected in response to all proteins (Fig 3, A) . In the absence of alum, both fusion proteins also induced Bet v 1-specific IgG 1 and IgE antibodies. However, only Bet v 1-NtCFlg induced noticeable Bet v 1-specific IgG 2a antibodies (Fig 3, A) . Compared with Bet v 1-NtCFlg, the antibody response induced by NtCFlg-Bet v 1 was delayed. Five immunizations with the mixture of Bet v 1 and NtCFlg were necessary to induce Bet v 1-specific IgG 1 , whereas Bet v 1-specific IgG 2a and IgE levels remained negligible. Immunization with Bet v 1 in the absence of alum induced no detectable antibody responses.
Splenocytes were stimulated with Bet v 1 and proliferative and cytokine responses were assessed to compare allergenspecific cellular responses in the different groups. Fig 3, B, shows that Bet v 1-induced proliferative responses were more pronounced in mice immunized with the fusion proteins compared with those immunized with Bet v 1 and the mixture of Bet v 1 and NtCFlg. Allergen-specific proliferation was greater in all groups immunized without alum, except for mice immunized with wild-type Bet v 1. Similar IFN-g/IL-4 ratios were found in all groups when immunized with and without alum, except for mice immunized with Bet v 1-NtCFlg. These mice showed a significantly higher IFN-g/IL-4 ratio in the absence of alum, indicating a more T H 1-like response that matches with the induction of Bet v 1-specific IgG 2a antibodies. Cytokine levels in unstimulated cultures were subtracted from levels in stimulated cultures.
Murine antibodies raised against Bet v 1-NtCFlg show blocking capacity
Bet v 1 was preincubated with pools of mouse sera collected before or after 5 immunizations with either Bet v 1, Bet v 1-NtCFlg, or NtCFlg-Bet v 1 adsorbed to alum and used to activate basophils from 6 patients with birch pollen allergy. Fig 3, B, shows that, compared with preimmune sera, sera from mice immunized with Bet v 1 and Bet v 1-NtCFlg significantly reduced basophil activation (P < .05). In contrast, sera from mice immunized with NtCFlg-Bet v 1 had no inhibitory effect.
DISCUSSION
To enhance the immunogenicity of Bet v 1 for improved efficacy of AIT, we genetically fused it N-and C-terminally with a truncated variant of the TLR5 ligand fliC, which is used as an adjuvant in various human vaccines. 28, 29 Bet v 1 and NtCFlg do not mutually interact because NtCFlg has no influence on functional IgE binding of Bet v 1 and Bet v 1 does not alter the TLR5-activating capacity of NtCFlg (see Fig E2 in this article' s Online Repository at www.jacionline.org). Both fusion proteins triggered TLR5 and caused mdDC maturation. TLR5 is expressed on the surfaces of many types of antigen-presenting cells similarly to TLR4. 30 Consequently, we expect that use of such fusion proteins can reduce the number of injections similar to AIT vaccines containing monophosphoryl lipid A. 6, 8 Beyond that, fliC has been shown to directly stimulate CD4 1 T cells, leading to enhanced proliferation and IFN-g production in memory T cells 31 and a higher suppressive potential in regulatory T cells. 32 Indeed, Bet v 1-NtCFlg displayed a stronger capacity in activation of naive and allergen-specific effector T cells than wild-type Bet v 1. Bet v 1-NtCFlg also polarized naive T lymphocytes to IFN-g production. Antigen processing of Bet v 1-NtCFlg retained the relevant T-cell epitopes of Bet v 1, which is a necessary prerequisite to target all types of allergen-specific T cells during AIT. In addition to enhanced immunogenicity, both fusion proteins displayed significantly lower functional IgE-binding capacity, indicating that their administration to allergic patients will trigger less IgE-mediated side effects. Finally, the fusion proteins induced Bet v 1-specific humoral and cellular responses in mice, even when not adsorbed to alum, which were not observed with wild-type Bet v 1 and clearly less pronounced with the mixture of Bet v 1 and NtCFlg. In the absence of alum, Bet v 1-NtCFlg induced Bet v 1-specific IgG 2a antibodies and a higher IFN-g/IL-4 ratio, indicating a T H 1-like response. These findings suggest that a vaccine based on this fusion protein can be devoid of alum, which additionally promotes the counterregulation of T H 2-like responses during AIT.
Antigen sequences have been added to fliC at the N-or Cterminus or within the hypervariable region without any loss of signaling through TLR5. 29, 33, 34 Also, our fusion proteins retained TLR5 activity and matched previous observations with flagellin from Listeria monocytogenes, [18] [19] [20] and the physical linkage of Bet v 1 and NtCFlg resulted in stronger immune responses than the mixture of both reagents (Fig 3) . However, the N-terminal variant displayed a clearly lower capacity to trigger TLR5 than the C-terminal fusion protein. The impaired capacity of NtCFlg-Bet v 1 to activate TLR5 was overcome by the addition of NtCFlg (see Fig E3 in this article' s Online Repository at www.jacionline.org). In contrast, NtCFlg did not affect TLR5 activation by Bet v 1-NtCFlg, demonstrating that this fusion protein fully activated TLR5. Further comparison of both hybrids revealed that Bet v 1-NtCFlg was also superior to NtCFlg-Bet v 1 in activation of mdDCs and allergen-specific T cells. Both fusion proteins bound significantly less Bet v 1-specific IgE from patients with birch pollen allergy but still induced Bet v 1-specific antibody production in mice. Again, slightly higher responses to Bet v 1-NtCFlg were observed. In the absence of alum, Bet v 1-NtCFlg induced an earlier and stronger Bet v 1-specific IgG 1 and IgG 2a response than NtCFlg-Bet v 1.
Testing the capacity of murine Bet v 1-specific antibodies to inhibit the binding of patients' IgE revealed a major difference between both fusion proteins. Sera from mice immunized with Bet v 1-NtCFlg inhibited the Bet v 1-mediated activation of basophils from patients with birch pollen allergy to the same degree as sera from mice immunized with Bet v 1. In contrast, sera from mice immunized with NtCFlg-Bet v 1 lacked this blocking capacity. These data suggest that a vaccine based solely on Bet v 1-NtCFlg will induce allergen-specific IgG antibodies, which inhibit IgE-mediated reactions. Bet v 1-NtCFlg was superior to NtCFlg-Bet v 1 in the inhibition of IgE binding to Bet v 1 and in basophil activation when used at low concentrations (Fig 2) . From these findings, we deduce that Bet v 1-NtCFlg contains more IgE epitopes of Bet v 1 and thereby induces diverse Bet v 1-specific IgG antibodies with sufficient affinity to block IgE binding. Thus the sequential order of allergen and fliC within fusion proteins is of major importance for the induction of blocking antibodies and needs to be carefully evaluated for each variant. In summary, Bet v 1-NtCFlg displays several advantages over wild-type Bet v 1, namely reduced allergenicity, enhanced immunogenicity, and intrinsic adjuvanticity. Therefore we consider Bet v 1-NtCFlg a promising vaccine candidate for AIT, which might be particularly interesting for sublingual immunotherapy (SLIT). Recently, SLIT with rBet v 1 has been demonstrated to be safe and efficacious in patients with birch pollen-induced rhinoconjunctivitis. 35 As previously observed for subcutaneous administration, 21 sublingual administration of Bet v 1 showed an efficacy consistent with that of SLIT with birch pollen extract. However, several patients dropped out of the trial because of treatment-associated IgE-mediated adverse side effects. To improve this situation, novel vaccines for AIT should be hypoallergenic and incorporate adjuvants that effectively stimulate the innate immune response and thereby enhance adaptive immune responses. Bet v 1-NtCFlg combines all these requirements with the additional advantages of recombinant protein production, such as easy standardization, batch-to-batch consistency, a constant allergen/adjuvant ratio, and, consequently, invariant immunologic characteristics. Furthermore, fusion proteins containing fliC and the otherwise poorly immunogenic influenza antigen M2e proved to be safe and immunogenic in clinical trials. 36, 37 Beyond that, fusion proteins of fliC and the influenza hemagglutinin antigen induced seroprotection in elderly human subjects. 38 Consequently, we propose Bet v 1-NtCFlg to be a promising vaccine candidate for conventional and sublingual AIT of birch pollen allergy.
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Clinical implications: Bet v 1-flagellin fusion proteins represent promising vaccines for birch pollen AIT. 
